Bridgetech Asia Limited ("BT Asia") is foremost in delivering web based predictive diagnostics to the Asian market. The Company’s strategy complements the irreversible global trend towards preventive medicine with a focus on chronic diseases and ophthalmology.
 

BT Asia is supporting Asia’s increasing need for non-invasive predictive diagnostics for early detection of disease. Asia’s population currently stands at 2 billion with a rapidly growing middle class.  As the population strives for a better quality of life and becomes more health conscious, the demand grows for more sophisticated and readily accessible non-invasive predictive diagnostics and preventive treatment options.

 

BT Asia’s mission is to contribute to the well-being of Asians through success in the marketplace. The Company has developed a strategy, leadership and clinical infrastructure to evaluate and analyze the best predictive diagnostics for Asia’s growing healthcare market. BT Asia has longstanding relationship with leading healthcare organizations in Asia, and close ties to government, regulatory and medical communities in these regions. Through these relationships, market demand, and most importantly, an existing local sales and distribution infrastructure, BT Asia is well poised to meet Asia’s growing healthcare needs.

Return to Top >